表紙
市場調査レポート

Flamel Technologies S.A. : 製品パイプライン分析

Flamel Technologies S.A. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 224580
出版日 ページ情報 英文 33 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
Flamel Technologies S.A. : 製品パイプライン分析 Flamel Technologies S.A. - Product Pipeline Review - 2015
出版日: 2015年08月31日 ページ情報: 英文 33 Pages
概要

Flamel Technologies S.A. は、満たされていない医療ニーズに対応できる薬剤の開発に取り組んでいる専門的製薬会社で、独自の薬物送達技術のプラットフォームを活用して新規化学物質 (NCEs) および新規生物学的物質(NBEs)の開発に取り組んでいます。

当レポートでは、Flamel Technologies S.A.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Flamel Technologies S.A.の基本情報

Flamel Technologies S.A.の概要

  • 主要情報
  • 企業情報

Flamel Technologies S.A.:R&Dの概要

  • 主な治療範囲

Flamel Technologies S.A.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Flamel Technologies S.A.:パイプライン製品の概況

Flamel Technologies S.A.▼治験段階にあるパイプライン製品

第I相にある製品/併用療法モダリティ

Flamel Technologies S.A.▼初期段階にあるパイプライン製品

前臨床段階にある製品/併用療法モダリティ

Flamel Technologies S.A.:開発段階が不明のパイプライン製品

  • 開発段階が不明の製品/併用療法モダリティ

Flamel Technologies S.A.:薬剤プロファイル

  • GLP-1 biobetter
  • hydromorphone hydrochloride
  • sodium oxybate
  • somatropin biobetter
  • Drug for Cardiovascular Disorders
  • tigecycline biobetter
  • Proteins for Undisclosed Indication
  • Small Molecules for Undisclosed Indication

Flamel Technologies S.A.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Flamel Technologies S.A.:休止中のプロジェクト

Flamel Technologies S.A.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • interferon alfa-2b biobetter
    • interferon beta-1a biobetter

Flamel Technologies S.A.:企業発表

Flamel Technologies S.A.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07361CDB

Summary

Global Markets Direct's, 'Flamel Technologies S.A. - Product Pipeline Review - 2015', provides an overview of the Flamel Technologies S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Flamel Technologies S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Flamel Technologies S.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Flamel Technologies S.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Flamel Technologies S.A.'s pipeline products

Reasons to buy

  • Evaluate Flamel Technologies S.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Flamel Technologies S.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Flamel Technologies S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Flamel Technologies S.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Flamel Technologies S.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Flamel Technologies S.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Flamel Technologies S.A. Snapshot
    • Flamel Technologies S.A. Overview
    • Key Information
    • Key Facts
  • Flamel Technologies S.A. - Research and Development Overview
    • Key Therapeutic Areas
  • Flamel Technologies S.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Flamel Technologies S.A. - Pipeline Products Glance
    • Flamel Technologies S.A. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Flamel Technologies S.A. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Flamel Technologies S.A. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Flamel Technologies S.A. - Drug Profiles
    • GLP-1 biobetter
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hydromorphone hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sodium oxybate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • somatropin biobetter
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Cardiovascular Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tigecycline biobetter
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Proteins for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Flamel Technologies S.A. - Pipeline Analysis
    • Flamel Technologies S.A. - Pipeline Products by Target
    • Flamel Technologies S.A. - Pipeline Products by Route of Administration
    • Flamel Technologies S.A. - Pipeline Products by Molecule Type
    • Flamel Technologies S.A. - Pipeline Products by Mechanism of Action
  • Flamel Technologies S.A. - Recent Pipeline Updates
  • Flamel Technologies S.A. - Dormant Projects
  • Flamel Technologies S.A. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • interferon alfa-2b biobetter
      • interferon beta-1a biobetter
  • Flamel Technologies S.A. - Company Statement
  • Flamel Technologies S.A. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Flamel Technologies S.A., Key Information
  • Flamel Technologies S.A., Key Facts
  • Flamel Technologies S.A. - Pipeline by Indication, 2015
  • Flamel Technologies S.A. - Pipeline by Stage of Development, 2015
  • Flamel Technologies S.A. - Monotherapy Products in Pipeline, 2015
  • Flamel Technologies S.A. - Partnered Products in Pipeline, 2015
  • Flamel Technologies S.A. - Partnered Products/ Combination Treatment Modalities, 2015
  • Flamel Technologies S.A. - Phase I, 2015
  • Flamel Technologies S.A. - Preclinical, 2015
  • Flamel Technologies S.A. - Unknown, 2015
  • Flamel Technologies S.A. - Pipeline by Target, 2015
  • Flamel Technologies S.A. - Pipeline by Route of Administration, 2015
  • Flamel Technologies S.A. - Pipeline by Molecule Type, 2015
  • Flamel Technologies S.A. - Pipeline Products by Mechanism of Action, 2015
  • Flamel Technologies S.A. - Recent Pipeline Updates, 2015
  • Flamel Technologies S.A. - Dormant Developmental Projects,2015
  • Flamel Technologies S.A. - Discontinued Pipeline Products, 2015
  • Flamel Technologies S.A., Subsidiaries

List of Figures

  • Flamel Technologies S.A. - Pipeline by Top 10 Indication, 2015
  • Flamel Technologies S.A. - Pipeline by Stage of Development, 2015
  • Flamel Technologies S.A. - Monotherapy Products in Pipeline, 2015
  • Flamel Technologies S.A. - Partnered Products in Pipeline, 2015
  • Flamel Technologies S.A. - Pipeline by Top 10 Target, 2015
  • Flamel Technologies S.A. - Pipeline by Top 10 Route of Administration, 2015
  • Flamel Technologies S.A. - Pipeline by Top 10 Molecule Type, 2015
  • Flamel Technologies S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top